Der Sheng Sun1, Yoon Ho Ko2,3, Sang Hoon Chun1, Eun Young Kim4, Jung-Sook Yoon5, Hye Sung Won1, Kwangil Yim6, Hye Won Hwang7, Soon Auck Hong7, Minho Lee8, Su Lim Lee9, Sung-Soo Kim10. 1. Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. koyoonho@catholic.ac.kr. 3. Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. koyoonho@catholic.ac.kr. 4. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 5. Uijeongbu St. Mary's Hospital Clinical Research Laboratory, The Catholic University of Korea, Seoul, Republic of Korea. 6. Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 7. Department of Pathology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. 8. Department of Life Science, Dongguk University-Seoul, Goyang, Republic of Korea. 9. Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 10. Department of Internal Medicine, Division of Gastroenterology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract
BACKGROUND: Noggin and RNA-binding protein for multiple splicing 2 (RBPMS2) are known to regulate the expression of smooth muscle cells, endothelial cells, and osteoblasts. However, the prognostic role of combined Noggin and RBPMS2 expression in resected gastric cancer (GC) is unclear. METHODS: A total of 163 patients with GC who underwent gastrectomy were included in this study. The expression of Noggin and RBPMS2 proteins in tumor cells at the tumor center and invasive front of resected GC was evaluated by immunohistochemistry, and in conjunction with clinicopathological parameters the patient survival was analyzed. RESULTS: RBPMS2 protein expression was high at the tumor center (n = 86, 52.8%) and low at the invasive front (n = 69, 42.3%), while Noggin protein expression was high in both tumor center (n = 91, 55.8%) and the invasive front (n = 90, 55.2%). Noggin expression at the invasive front and tumor center was significantly decreased in advanced T stage, non-intestinal-type (invasive front, P = 0.008 and P < 0.001; tumor center lesion, P = 0.013 and P = 0.001). RBPMS2 expression at the invasive front was significantly decreased in non-intestinal-type and positive lymphatic invasion (P < 0.001 and P = 0.013). Multivariate analysis revealed that high Noggin protein expression of the invasive front was an independent prognostic factor for overall survival (hazard ratio [HR], 0.58; 95% confidence interval [CI]; 0.35-0.97, P < 0.036), but not at the tumor center (HR, 1.35; 95% CI; 0.81-2.26, P = 0.251). CONCLUSIONS: Our study indicates that high Noggin expression is a crucial prognostic factor for favorable outcomes in patients with resected GC.
BACKGROUND:Noggin and RNA-binding protein for multiple splicing 2 (RBPMS2) are known to regulate the expression of smooth muscle cells, endothelial cells, and osteoblasts. However, the prognostic role of combined Noggin and RBPMS2 expression in resected gastric cancer (GC) is unclear. METHODS: A total of 163 patients with GC who underwent gastrectomy were included in this study. The expression of Noggin and RBPMS2 proteins in tumor cells at the tumor center and invasive front of resected GC was evaluated by immunohistochemistry, and in conjunction with clinicopathological parameters the patient survival was analyzed. RESULTS:RBPMS2 protein expression was high at the tumor center (n = 86, 52.8%) and low at the invasive front (n = 69, 42.3%), while Noggin protein expression was high in both tumor center (n = 91, 55.8%) and the invasive front (n = 90, 55.2%). Noggin expression at the invasive front and tumor center was significantly decreased in advanced T stage, non-intestinal-type (invasive front, P = 0.008 and P < 0.001; tumor center lesion, P = 0.013 and P = 0.001). RBPMS2 expression at the invasive front was significantly decreased in non-intestinal-type and positive lymphatic invasion (P < 0.001 and P = 0.013). Multivariate analysis revealed that high Noggin protein expression of the invasive front was an independent prognostic factor for overall survival (hazard ratio [HR], 0.58; 95% confidence interval [CI]; 0.35-0.97, P < 0.036), but not at the tumor center (HR, 1.35; 95% CI; 0.81-2.26, P = 0.251). CONCLUSIONS: Our study indicates that high Noggin expression is a crucial prognostic factor for favorable outcomes in patients with resected GC.
Entities:
Keywords:
Gastric cancer; Noggin; Prognosis; RNA-binding protein for multiple splicing 2 (RBPMS2)
Authors: Mark T Uhlik; Jiangang Liu; Beverly L Falcon; Seema Iyer; Julie Stewart; Hilal Celikkaya; Marguerita O'Mahony; Christopher Sevinsky; Christina Lowes; Larry Douglass; Cynthia Jeffries; Diane Bodenmiller; Sudhakar Chintharlapalli; Anthony Fischl; Damien Gerald; Qi Xue; Jee-Yun Lee; Alberto Santamaria-Pang; Yousef Al-Kofahi; Yunxia Sui; Keyur Desai; Thompson Doman; Amit Aggarwal; Julia H Carter; Bronislaw Pytowski; Shou-Ching Jaminet; Fiona Ginty; Aejaz Nasir; Janice A Nagy; Harold F Dvorak; Laura E Benjamin Journal: Cancer Res Date: 2016-05-01 Impact factor: 12.701